On April 11, the U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA) as a first-line treatment for patients with advanced NSCLC who have a score of 1% or higher on the PD-L1 biomarker test. The approval was based on KEYNOTE-042 trial which demonstrated statistically significant OS improvements for those randomized to pembrolizumab compared with chemotherapy.
[…] post FDA Approves First-Line Treatment for NSCLC with PD-L1 Biomarker appeared first on Lung Cancer […]
Stage 4 nscl ardeno
21 cycle of Keytruda then progression
Now on cisplatin pemetrexed third cycle doing ok sickly and low white bloods cells what’s next for me
Hi Catherine, please know that you are not alone. If you have questions or would just like someone to talk to, please reach out to our HelpLine at 1-800-298-2436 or support@lungcanceralliance.org. Sending positive vibes your way!